# Counterpain PXM Versus Diclofenac Versus Piroxicam

> **NCT07475663** · PHASE3 · COMPLETED · sponsor: **Taisho Pharmaceutical Indonesia** · enrollment: 180 (actual)

## Conditions studied

- Ankle Sprain
- Back Pain
- Osteoarthritis (OA) of the Knee
- Tennis Elbow
- Runner's Knee

## Interventions

- **DRUG:** Piroxicam plus Counterirritant (brand name Counterpain® PXM).
- **DRUG:** Diclofenac Sodium 10 mg (Brand Name Hotin® DCL)
- **DRUG:** Piroxicam 0.5% (Brand name Pirofel® gel)

## Key facts

- **NCT ID:** NCT07475663
- **Lead sponsor:** Taisho Pharmaceutical Indonesia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-11-04
- **Primary completion:** 2026-02-12
- **Final completion:** 2026-02-12
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07475663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07475663, "Counterpain PXM Versus Diclofenac Versus Piroxicam". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07475663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*